The Canakinumab Anti-Inflammatory Thrombosis Outcome Study trial also provided proof for the inflammation hypothesis of atherosclerosis [30], and IL-1β inhibition highlighted the potential of anti-inflammatory therapies to improve the clinical outcomes of CVDs. This evidence concerns the gene IL1B and deep vein thrombosis.